EP0634938A4 - Gegen cd33 verwandte oberflächen-antigene gerichtete immuntoxine. - Google Patents

Gegen cd33 verwandte oberflächen-antigene gerichtete immuntoxine.

Info

Publication number
EP0634938A4
EP0634938A4 EP93912143A EP93912143A EP0634938A4 EP 0634938 A4 EP0634938 A4 EP 0634938A4 EP 93912143 A EP93912143 A EP 93912143A EP 93912143 A EP93912143 A EP 93912143A EP 0634938 A4 EP0634938 A4 EP 0634938A4
Authority
EP
European Patent Office
Prior art keywords
directed against
surface antigens
related surface
immunotoxins directed
immunotoxins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP93912143A
Other languages
English (en)
French (fr)
Other versions
EP0634938A1 (de
Inventor
Michael G Rosenblum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Priority to EP04017939A priority Critical patent/EP1656950A1/de
Publication of EP0634938A1 publication Critical patent/EP0634938A1/de
Publication of EP0634938A4 publication Critical patent/EP0634938A4/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP93912143A 1992-04-10 1993-04-08 Gegen cd33 verwandte oberflächen-antigene gerichtete immuntoxine. Ceased EP0634938A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04017939A EP1656950A1 (de) 1992-04-10 1993-04-08 Gegen CD33-bezogene Oberflächenantigene gerichtete immunotoxine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86669392A 1992-04-10 1992-04-10
US866693 1992-04-10
PCT/US1993/003284 WO1993020848A1 (en) 1992-04-10 1993-04-08 Immunotoxins directed against cd33 related surface antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP04017939A Division EP1656950A1 (de) 1992-04-10 1993-04-08 Gegen CD33-bezogene Oberflächenantigene gerichtete immunotoxine

Publications (2)

Publication Number Publication Date
EP0634938A1 EP0634938A1 (de) 1995-01-25
EP0634938A4 true EP0634938A4 (de) 1998-06-03

Family

ID=25348185

Family Applications (2)

Application Number Title Priority Date Filing Date
EP93912143A Ceased EP0634938A4 (de) 1992-04-10 1993-04-08 Gegen cd33 verwandte oberflächen-antigene gerichtete immuntoxine.
EP04017939A Withdrawn EP1656950A1 (de) 1992-04-10 1993-04-08 Gegen CD33-bezogene Oberflächenantigene gerichtete immunotoxine

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP04017939A Withdrawn EP1656950A1 (de) 1992-04-10 1993-04-08 Gegen CD33-bezogene Oberflächenantigene gerichtete immunotoxine

Country Status (13)

Country Link
EP (2) EP0634938A4 (de)
JP (1) JP3949158B2 (de)
KR (1) KR950700760A (de)
CN (1) CN1056084C (de)
AU (1) AU675226B2 (de)
CA (1) CA2133838C (de)
FI (1) FI944730A (de)
IL (1) IL105344A (de)
NO (1) NO314686B1 (de)
NZ (1) NZ252799A (de)
RU (1) RU2127122C1 (de)
WO (1) WO1993020848A1 (de)
ZA (1) ZA932523B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599505B1 (en) 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
AUPN115095A0 (en) * 1995-02-15 1995-03-09 Butt, Henry Lawrence Analysis of and compositions and methods for the treatment of disease
KR101021124B1 (ko) * 2001-05-24 2011-03-14 지모제넥틱스, 인코포레이티드 Ｔａｃｉ-면역글로불린 융합 단백질
TW200726776A (en) * 2005-07-29 2007-07-16 Friedrich Alexander University Of Erlangen Nuremberg CD33-specific single-chain immunotoxin and methods of use
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
EP2777714A1 (de) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Verfahren zur Herstellung eines Immunoliganden/Nutzlastkonjugats durch ein Sequenz-spezifisches Transpeptidase Enzym
JP7497953B2 (ja) 2015-06-12 2024-06-11 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
CN116063499A (zh) * 2015-06-12 2023-05-05 艾利妥 抗cd33抗体及其使用方法
WO2019028283A1 (en) 2017-08-03 2019-02-07 Alector Llc ANTI-CD33 ANTIBODIES AND METHODS OF USE
CN113801229A (zh) 2018-08-31 2021-12-17 艾利妥 抗cd33抗体及其使用方法
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0350230A2 (de) * 1988-07-07 1990-01-10 RESEARCH DEVELOPMENT FOUNDATION (a Nevada corporation) Immunokonjugate für Krebsdiagnostik und -therapie
WO1991009058A1 (en) * 1989-12-14 1991-06-27 Sloan-Kettering Institute For Cancer Research Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0350230A2 (de) * 1988-07-07 1990-01-10 RESEARCH DEVELOPMENT FOUNDATION (a Nevada corporation) Immunokonjugate für Krebsdiagnostik und -therapie
WO1991009058A1 (en) * 1989-12-14 1991-06-27 Sloan-Kettering Institute For Cancer Research Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MAN SUNG CO: "CHIMERIC AND HUMANIZED ANTIBODIES WITH SPECIFICITY FOR THE CD33 ANTIGEN1", JOURNAL OF IMMUNOLOGY, vol. 148, no. 4, 15 February 1992 (1992-02-15), pages 1149 - 1154, XP000368716 *
SCHEINBERG D A ET AL: "A PHASE I TRIAL OF MONOCLONAL ANTIBODY M195 IN ACUTE MYELOGENOUS LEUKEMIA: SPECIFIC BONE MARROW TERGETING AND INTERNALIZATION OF RADIONUCLIDE", JOURNAL OF CLINICAL ONCOLOGY, vol. 9, no. 3, 1 March 1991 (1991-03-01), pages 478 - 490, XP000564602 *
SCHEINBERG ET AL.: "Humanized and Mouse Anti-CD33-Gelonin Immunotoxins for Myeloid Leukemias", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 33, March 1992 (1992-03-01), pages 346, XP002061680 *
See also references of WO9320848A1 *

Also Published As

Publication number Publication date
JPH08501059A (ja) 1996-02-06
FI944730A0 (fi) 1994-10-07
JP3949158B2 (ja) 2007-07-25
KR950700760A (ko) 1995-02-20
EP0634938A1 (de) 1995-01-25
FI944730A (fi) 1994-10-07
AU675226B2 (en) 1997-01-30
CN1078401A (zh) 1993-11-17
IL105344A0 (en) 1993-08-18
CN1056084C (zh) 2000-09-06
WO1993020848A1 (en) 1993-10-28
KR100291377B1 (de) 2001-09-17
CA2133838C (en) 2003-07-29
NZ252799A (en) 1996-10-28
NO314686B1 (no) 2003-05-05
CA2133838A1 (en) 1993-10-28
ZA932523B (en) 1994-10-08
NO943776L (no) 1994-11-25
RU2127122C1 (ru) 1999-03-10
NO943776D0 (no) 1994-10-07
IL105344A (en) 2000-06-29
EP1656950A1 (de) 2006-05-17
AU4280193A (en) 1993-11-18

Similar Documents

Publication Publication Date Title
EP0597463A3 (en) Thermotherapiesonde.
EP0580285A3 (de) Selbsttätige Wiedereinschalter.
GB9310820D0 (en) Surface modification
GR3021407T3 (en) Drop-producing device.
EP0634938A4 (de) Gegen cd33 verwandte oberflächen-antigene gerichtete immuntoxine.
EP0572808A3 (de) Antiblockierregelsystem.
GB2273010B (en) Electric-supply-switch relay-circuit
ZA931772B (en) Imidazolyl-substituted phenylacetamides.
ZA93770B (en) Herbicides.
EP0599191A3 (de) Motordrehzahlregler-Schaltkreis.
GB9101424D0 (en) Fluid transportation
EP0592354A3 (de) Vakuum-Zentrifuge.
GB9217535D0 (en) Recreational surface
ZA93432B (en) Improved packaging element.
EP0571361A3 (de) Portioniervorrichtung.
GB9221450D0 (en) The wropod
GB9224339D0 (en) Surface following device
ZA94532B (en) Surface covering material.
EP0644890A4 (de) Oligonucleotid-polyamide konjugate.
ZA928854B (en) Carrying device.
GB9203301D0 (en) The auto-pour
GB9219865D0 (en) The exerthighs
GB9213408D0 (en) The aquasave
GB9217514D0 (en) The bathmaster
GB9214143D0 (en) The napbag

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941010

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19980421

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19990217

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APAD Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOS REFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20040820

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE